Fuko Hirano
Overview
Explore the profile of Fuko Hirano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kondo N, Yonezawa M, Hirano F, Temma T
Molecules
. 2025 Mar;
30(5).
PMID: 40076236
Glucagon-like peptide-1 receptor (GLP-1R) is an emerging critical target for the diagnosis and treatment of various diseases. Radiolabeled exendin-4 (Ex-4), a GLP-1R agonist, has been widely used as an imaging...
2.
Miyazaki A, Kanai Y, Wakamori K, Mizuguchi S, Futatsugi M, Hirano F, et al.
EJNMMI Radiopharm Chem
. 2024 Jun;
9(1):46.
PMID: 38834900
Background: Signal transducer and activator of transcription 3 (STAT3) is a protein that regulates cell proliferation and differentiation, and it is attracting attention as a new index for evaluating cancer...
3.
Hirano F, Kondo N, Murata Y, Sudani A, Temma T
Bioorg Chem
. 2023 Nov;
142:106940.
PMID: 37939508
A [B]boron agent and a nuclear imaging probe for pharmacokinetic estimation form the fundamental pair in successful boron neutron capture therapy (BNCT). However, 4-[B]borono-l-phenylalanine (BPA), used in clinical BNCT, has...
4.
Kondo N, Hirano F, Temma T
Pharmaceutics
. 2022 May;
14(5).
PMID: 35631692
Although 4-borono-l-phenylalanine (4-BPA) is currently the only marketed agent available for boron neutron capture therapy (BNCT), its low water solubility raises concerns. In this study, we synthesized 3-borono-l-phenylalanine (3-BPA), a...